Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Xenetic Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

EXPANDED COLLABORATIVE RESEARCH INITIATIVES REINFORCE THE COMPANY'S LONG-TERM DNASE DEVELOPMENT STRATEGY ONGOING GENERATION OF TRANSLATIONAL DATA DESIGNED TO SUPPORT FUTURE CLINICAL DEVELOPMENT AND DEEPEN UNDERSTANDING OF DNASE I-MEDIATED NET TARGETING CONTINUED ROYALTY GENERATION PROVIDES RECURRING, NON-DILUTIVE FUNDING TO SUPPORT CONTINUED INVESTMENT IN CORE DEVELOPMENT PROGRAMS FRAMINGHAM, MA / ACCESS NEWSWIRE / AUGUST 7, 2026 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026, AND PROVIDED A CORPORATE UPDATE ON CONTINUED EXECUTION OF ITS LONG-TERM STRATEGY TO ADVANCE ITS PROPRIETARY DNASE PLATFORM THROUGH SCIENTIFIC COLLABORATION AND TRANSLATIONAL RESEARCH. RECENT HIGHLIGHTS POSITIVE PRECLINICAL AND TRANSLATIONAL DATA PRESENTED AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING DEMONSTRATING THAT DNASE I SIGNIFICANTLY ENHANCED CAR T-CELL EXPANSION, PERSISTENCE, TUMOR CONTROL AND SURVIVAL ACROSS PRECLINICAL HEMATOLOGIC CANCER MODELS ANNOUNCED THAT COLLABORATION PARTNER, PERINESS LTD.

XENETIC BIOSCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS STRENGTHENED SCIENTIFIC FOUNDATION SUPPORTING CONTINUED ADVANCEMENT OF PROPRIETARY DNASE PLATFORM

COMPANY EVALUATING SYSTEMIC RECOMBINANT HUMAN DNASE I IN COMBINATION WITH ANTI-CD19 CAR T CELLS TARGETING LYMPHOMA PATIENTS IN STABLE OR PROGRESSIVE DISEASE AT LYMPHODEPLETION COMPANY REPORTED STRONG POSITIVE PRECLINICAL RESULTS DEMONSTRATING SIGNIFICANTLY ENHANCED ANTI-TUMOR ACTIVITY OF ANTI-CD-19 CAR T CELLS WHEN COMBINED WITH DNASE I IN MULTIPLE PRECLINICAL MODELS OF HEMATOLOGIC CANCERS INVESTIGATOR INITIATED STUDY TO BE CONDUCTED AT TEL-AVIV SOURASKY MEDICAL CENTER ("SOURASKY CENTER") FRAMINGHAM, MA / ACCESS NEWSWIRE / JUNE 4, 2026 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THAT ITS COLLABORATION PARTNER, PERINESS LTD. (PERINESS), HAS INFORMED THE COMPANY THAT IT RECEIVED FORMAL APPROVAL FROM THE ISRAELI MINISTRY OF HEALTH AND THE RESPECTIVE INSTITUTIONAL REVIEW BOARD TO CONDUCT AN EXPLORATORY CLINICAL STUDY OF A COMBINATION SYSTEMIC DNASE I WITH ANTI-CD19 CAR T CELLS IN LARGE B CELL LYMPHOMA (LBCL) PATIENTS.

XENETIC BIOSCIENCES, INC. ANNOUNCES THAT ITS COLLABORATION PARTNER RECEIVED APPROVAL FROM THE ISRAELI MINISTRY OF HEALTH TO CONDUCT EXPLORATORY, INVESTIGATOR INITIATED STUDY OF DNASE I IN COMBINATION WITH ANTI-CD19 CAR T CELLS IN LARGE B-CELL LYMPHOMA

NEW PRECLINICAL AND TRANSLATIONAL FINDINGS POSITION DNASE I AS A POTENTIALLY TRANSFORMATIVE ADJUNCT THERAPY FOR CAR-T TREATMENT IN AGGRESSIVE B CELL MALIGNANCIES DATA HIGHLIGHT POTENTIAL OF DNASE I TO IMPROVE CAR-T CELL EXPANSION, REDUCE EXHAUSTION AND ENHANCE TUMOR CONTROL ACROSS HEMATOLOGIC CANCER MODELS FINDINGS SUPPORT CONTINUED CLINICAL DEVELOPMENT OF DNASE I AS A COMBINATORIAL STRATEGY TO AUGMENT CAR-T CELL THERAPIES IN DIFFICULT-TO-TREAT CANCERS DATA TO BE PRESENTED TODAY AS A POSTER PRESENTATION AT THE ASCO 2026 ANNUAL MEETING FRAMINGHAM, MA / ACCESS NEWSWIRE / JUNE 1, 2026 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED POSITIVE PRECLINICAL DATA WILL BE PRESENTED AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING DEMONSTRATING THAT DNASE I SIGNIFICANTLY ENHANCES CAR-T CELL EXPANSION, PERSISTENCE, AND ANTITUMOR EFFICACY IN AGGRESSIVE HEMATOLOGIC CANCER MODELS. PRESENTATION DETAILS: SESSION TITLE: HEMATOLOGIC MALIGNANCIES - PLASMA CELL DYSCRASIA (POSTER SESSION) ABSTRACT TITLE: TARGETING CFDNA AND NETS WITH DNASE I TO AUGMENT CAR-T CELL FUNCTION AND ANTITUMOR EFFICACY POSTER BOARD: 410 PRESENTATION DATE & TIME: JUNE 1, 2026, 9:00 AM - 12:00 PM CDT PRESENTER: ALEXEY V.

XENETIC BIOSCIENCES SHOWCASES COMPELLING ASCO 2026 DATA DEMONSTRATING DNASE I SIGNIFICANTLY ENHANCES CAR-T CELL PERSISTENCE, TUMOR CONTROL, AND SURVIVAL

ADVANCEMENTS ACROSS INVESTIGATOR-INITIATED STUDIES, TRANSLATIONAL RESEARCH AND MANUFACTURING ACTIVITIES SUPPORTING FUTURE CLINICAL DEVELOPMENT STRENGTHENED FINANCIAL PROFILE WITH CONTINUED ROYALTY REVENUE GROWTH ENDED FIRST QUARTER 2026 WITH APPROXIMATELY $7.3 MILLION IN CASH WHILE CONTINUING EVALUATION OF STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE FRAMINGHAM, MA / ACCESS NEWSWIRE / MAY 13, 2026 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026 AND PROVIDED A CORPORATE UPDATE ON THE ADVANCEMENT OF ITS INNOVATIVE DNASE ONCOLOGY PLATFORM. RECENT HIGHLIGHTS GENERATED ROBUST TRANSLATIONAL DATA SUPPORTING THE DNASE I PLATFORM ACROSS MULTIPLE ONCOLOGY SETTINGS COMPLETED PROCESS IMPROVEMENT AND ANALYTICAL DEVELOPMENT ACTIVITIES SUPPORTING FUTURE CLINICAL MANUFACTURING READINESS ESTABLISHED TRANSLATIONAL AND BIOMARKER INSIGHTS INTENDED TO HELP INFORM AND DE-RISK FUTURE CLINICAL TRIAL DESIGN COLLABORATION PARTNER RECEIVED APPROVAL FROM ISRAELI MINISTRY OF HEALTH TO CONDUCT INVESTIGATOR-INITIATED EXPLORATORY STUDY OF DNASE I IN COMBINATION WITH ANTI-CD19 CAR T CELLS IN LARGE B-CELL LYMPHOMA "WE ENTERED 2026 WITH A CLEAR FOCUS ON ADVANCING THE TRANSLATIONAL, MANUFACTURING AND CLINICAL FOUNDATION OF OUR DNASE I PLATFORM WHILE MAINTAINING FINANCIAL DISCIPLINE," SAID JAMES PARSLOW, INTERIM CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER OF XENETIC.

XENETIC BIOSCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS CONTINUED ADVANCEMENT OF DNASE ONCOLOGY PLATFORM

FRAMINGHAM, MA / ACCESS NEWSWIRE / APRIL 22, 2026 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THAT ITS ABSTRACT HAS BEEN ACCEPTED FOR PRESENTATION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, TAKING PLACE MAY 29 - JUNE 2, 2026, IN CHICAGO, IL. THE ACCEPTED ABSTRACT, TITLED "TARGETING CFDNA AND NETS WITH DNASE I TO AUGMENT CAR T CELL FUNCTION AND ANTITUMOR EFFICACY," HIGHLIGHTS PRECLINICAL RESEARCH SUPPORTING XENETIC'S DNASE-BASED THERAPEUTIC APPROACH DESIGNED TO ENHANCE CAR T-CELL ACTIVITY AND IMPROVE ANTITUMOR RESPONSES.

XENETIC BIOSCIENCES, INC. ANNOUNCES ABSTRACT ACCEPTANCE FOR PRESENTATION AT THE 2026 ASCO ANNUAL MEETING

ENCOURAGING PRECLINICAL AND TRANSLATIONAL DATA SUPPORTING DNASE-BASED APPROACHES TO TARGET NETS IN DIFFICULT-TO-TREAT CANCERS STRATEGIC FOCUS ON INVESTIGATOR-INITIATED EXPLORATORY STUDIES AND INSTITUTIONAL COLLABORATIONS CONTINUED PROGRESS TOWARD IND-ENABLING ACTIVITIES FOR DNASE I PROGRAM ENDED THE YEAR WITH $7.9 MILLION OF CASH TO FUND OPERATIONS FRAMINGHAM, MA / ACCESS NEWSWIRE / MARCH 13, 2026 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025. RECENT HIGHLIGHTS EXPANDED AND PRESENTED PRECLINICAL AND TRANSLATIONAL EVIDENCE SUPPORTING NEUTROPHIL EXTRACELLULAR TRAPS (NETS) AS DRIVERS OF CANCER PROGRESSION AND HIGHLIGHTING THE THERAPEUTIC POTENTIAL OF DEOXYRIBONUCLEASE (DNASE) -BASED INTERVENTIONS; PROGRESSED INVESTIGATOR-INITIATED EXPLORATORY STUDIES IN ISRAEL EVALUATING DNASE I IN COMBINATION WITH STANDARD-OF-CARE AND IMMUNOTHERAPY PLATFORMS, INCLUDING: ONGOING PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) STUDY; PROPOSED LARGE B-CELL LYMPHOMA (LBCL) STUDY IN COMBINATION WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY; ADVANCED CLINICAL MANUFACTURING ACTIVITIES FOR DNASE I TOWARD INVESTIGATIONAL NEW DRUG (IND) APPLICATION; CURRENT FOCUS ON MECHANISM-OF-ACTION AND TRANSLATIONAL RESEARCH STUDIES SUPPORTED BY ENCOURAGING CAR-T PROOF-OF-CONCEPT STUDIES WITH SCRIPPS RESEARCH; AND PURSUING STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE.

XENETIC BIOSCIENCES, INC. REPORTS FULL YEAR 2025 FINANCIAL RESULTS

ADJOURNS 2025 ANNUAL MEETING OF STOCKHOLDERS URGES STOCKHOLDERS WHO HAVE NOT VOTED TO GET VOTES IN FRAMINGHAM, MA / ACCESS NEWSWIRE / DECEMBER 11, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THAT ITS 2025 ANNUAL MEETING OF STOCKHOLDERS (THE "ANNUAL MEETING") WAS CONVENED AND ADJOURNED WITHOUT ANY BUSINESS CONDUCTED DUE TO LACK OF THE REQUIRED QUORUM. A QUORUM IS NECESSARY TO HOLD THE ANNUAL MEETING.

XENETIC BIOSCIENCES, INC. ANNOUNCES ADJOURNMENT OF 2025 ANNUAL MEETING

FRAMINGHAM, MA / ACCESS NEWSWIRE / NOVEMBER 19, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED IT HAS EXECUTED A 4-MONTH EXTENSION OF ITS COLLABORATION WITH THE SCRIPPS RESEARCH INSTITUTE ("SCRIPPS RESEARCH") AND THE LAB OF DR. ALEXEY STEPANOV, INSTITUTE INVESTIGATOR AT SCRIPPS RESEARCH EFFECTIVE NOVEMBER 1, 2025, TO ADVANCE THE DEVELOPMENT OF THE COMPANY'S RESEARCH AND DEVELOPMENT PROGRAM EVALUATING THE COMBINATION OF SYSTEMIC DNASE I AND CAR T-CELL THERAPIES. XENETIC'S SYSTEMIC DNASE I CANDIDATE, XBIO-015, IS CURRENTLY IN PRECLINICAL DEVELOPMENT IN COMBINATION WITH CAR-T CELL THERAPY FOR BOTH HEMATOLOGIC AND SOLID TUMORS.

XENETIC BIOSCIENCES, INC. EXTENDS RESEARCH AND DEVELOPMENT COLLABORATION WITH INSTITUTE INVESTIGATOR AT SCRIPPS RESEARCH TO ADVANCE DNASE PLATFORM

CONTINUED EXECUTION ON COLLABORATIONS AND EXPLORATORY INVESTIGATOR-INITIATED STUDIES WITH INSTITUTIONAL PARTNERS SECURED NET PROCEEDS OF APPROXIMATELY $3.9 MILLION FROM OCTOBER 2025 OFFERING FRAMINGHAM, MA / ACCESS NEWSWIRE / NOVEMBER 13, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER 2025. "WE ARE STEADILY BUILDING THE FOUNDATION FOR POTENTIALLY TRANSFORMATIVE PROGRESS IN THE ONCOLOGY TREATMENT PARADIGM AS WE ADVANCE OUR SYSTEMIC DNASE I PROGRAM IN COMBINATION WITH ESTABLISHED CANCER THERAPIES," COMMENTED JAMES PARSLOW, INTERIM CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER OF XENETIC.

XENETIC BIOSCIENCES, INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

FRAMINGHAM, MA / ACCESS NEWSWIRE / OCTOBER 10, 2025 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNO-ONCOLOGY TECHNOLOGIES ADDRESSING DIFFICULT TO TREAT CANCERS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN OFFERING OF 735,000 SHARES OF COMMON STOCK AT A PRICE TO THE PUBLIC OF $6.12 PER SHARE, FOR GROSS PROCEEDS OF APPROXIMATELY $4.5 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES. ALL SHARES OF COMMON STOCK ARE BEING OFFERED BY XENETIC.

Xenetic Biosciences, Inc.

XBIO

Price

Financial Reports

No items found.

Press Releases

Xenetic Biosciences, Inc.

XBIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

XBIO